Novo Holdings invests EUR 86 million in 21st.BIO, a new bioindustrial scale-up company building on technology base from Novozymes COPENHAGEN, DENMARK — December 21, 2021. Novo Holdings, a leading international life sciences investor, today announced a significant investment in 21st.BIO A/S – a new D.
Financing co-led by Ysios Capital and Forbion Growth NorthSea Therapeutics B.V., ('NST') a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis
Organon (NYSE: OGN), a global women’s healthcare company, today announced the completion of its acquisition of Forendo Pharma, a clinical-stage drug development company focused on novel treatments in women’s health. Forendo’s lead candidate, FOR-6219, is an investigational, potentially first-in-class oral 17ß-hydroxysteroid dehydrogenase type 1 (HSD17B1) inhibitor entering Phase 2 clinical development for endometriosis.
The Nordic life sciences scene is getting an injection of cash. Led by centers such as the Karolinska Institutet and Copenhagen University, the region leads the way in research in the EU by many metrics but has traditionally lacked the vibrant VC scene needed to build large numbers of biotechs. Eir Ventures wants to help change that.
/PRNewswire/ HealthCap, a leading European life sciences venture capital firm, is delighted to announce that Dr. Mårten Steen, MD, PhD, has been appointed.